Dobre A, Nedelcu R, Turcu G, Brinzea A, Struna I, Tudorache G
Am J Clin Dermatol. 2024; 26(1):45-59.
PMID: 39572470
PMC: 11742465.
DOI: 10.1007/s40257-024-00900-0.
Vidovic D, Simms G, Pasternak S, Walsh M, Peltekian K, Stein J
Front Immunol. 2021; 12:678028.
PMID: 34122442
PMC: 8190543.
DOI: 10.3389/fimmu.2021.678028.
Bhandari B, Basyal B, Sarao M, Nookala V, Thein Y
Cureus. 2020; 12(4):e7870.
PMID: 32489725
PMC: 7255534.
DOI: 10.7759/cureus.7870.
Atteritano M, Mazzaferro S, Mantuano S, Bagnato G, Bagnato G
Cytotechnology. 2015; 68(2):313-8.
PMID: 26012953
PMC: 4754247.
DOI: 10.1007/s10616-014-9782-4.
Rallis E, Bournia V, Verros C, Iliopoulos A
Case Rep Med. 2015; 2015:315490.
PMID: 25815013
PMC: 4359804.
DOI: 10.1155/2015/315490.
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008).
Lacouture M, Morris J, Lawrence D, Tan A, Olencki T, Shapiro G
Cancer Immunol Immunother. 2015; 64(4):437-46.
PMID: 25579378
PMC: 6730642.
DOI: 10.1007/s00262-015-1653-0.
Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.
Morris J, Tan A, Olencki T, Shapiro G, Dezube B, Reiss M
PLoS One. 2014; 9(3):e90353.
PMID: 24618589
PMC: 3949712.
DOI: 10.1371/journal.pone.0090353.
Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.
Peluso R, Cafaro G, Di Minno A, Iervolino S, Ambrosino P, Lupoli G
Clin Rheumatol. 2013; 32(6):743-53.
PMID: 23588881
DOI: 10.1007/s10067-013-2252-0.
Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer.
Kouklakis G, Efremidou E, Pitiakoudis M, Liratzopoulos N, Polychronidis A
Drug Des Devel Ther. 2013; 7:195-9.
PMID: 23569358
PMC: 3615922.
DOI: 10.2147/DDDT.S41889.
Targeting the TGFβ signalling pathway in disease.
Akhurst R, Hata A
Nat Rev Drug Discov. 2012; 11(10):790-811.
PMID: 23000686
PMC: 3520610.
DOI: 10.1038/nrd3810.
Psoriatic disease and tuberculosis nowadays.
Balato N, DI Costanzo L, Ayala F, Balato A, Sanduzzi A, Bocchino M
Clin Dev Immunol. 2012; 2012:747204.
PMID: 22645622
PMC: 3356875.
DOI: 10.1155/2012/747204.
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.
Mercer L, Green A, Galloway J, Davies R, Lunt M, Dixon W
Ann Rheum Dis. 2012; 71(6):869-74.
PMID: 22241900
PMC: 3371225.
DOI: 10.1136/annrheumdis-2011-200622.
Roles of the immune system in skin cancer.
Rangwala S, Tsai K
Br J Dermatol. 2011; 165(5):953-65.
PMID: 21729024
PMC: 3197980.
DOI: 10.1111/j.1365-2133.2011.10507.x.
TNF-α inhibitors: are they carcinogenic?.
Raval G, Mehta P
Drug Healthc Patient Saf. 2011; 2:241-7.
PMID: 21701636
PMC: 3108710.
DOI: 10.2147/DHPS.S7829.
A practical approach to monitoring patients on biological agents for the treatment of psoriasis.
Emer J, Frankel A, Zeichner J
J Clin Aesthet Dermatol. 2010; 3(8):20-6.
PMID: 20877538
PMC: 2945861.
Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease.
Long M, Herfarth H, Pipkin C, Porter C, Sandler R, Kappelman M
Clin Gastroenterol Hepatol. 2009; 8(3):268-74.
PMID: 20005977
PMC: 2838486.
DOI: 10.1016/j.cgh.2009.11.024.
Atypical carcinoid tumor of the thymus with ectopic ACTH production developed during the course of etanercept treatment--case report.
Simsek I, Pay S, Dinc A, Erdem H, Kurt B
Clin Rheumatol. 2006; 26(9):1561-2.
PMID: 17061154
DOI: 10.1007/s10067-006-0454-4.
Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab.
Chen S, Cummings O, Hartley M, Filomena C, Cho W
Dig Dis Sci. 2006; 51(5):952-5.
PMID: 16670938
DOI: 10.1007/s10620-005-9009-9.
